Recent News

• 06.01.2026 - Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
• 05.29.2026 - Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes
• 05.22.2026 - Agios’ PYRUKYND® (mitapivat) Approved in the European Union for Adults with Thalassemia
• 05.12.2026 - Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
• 05.12.2026 - Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias
• 04.29.2026 - Agios Reports First Quarter 2026 Financial Results and Provides Business Update
• 04.06.2026 - Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET

Recent Filings

• 05.15.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.06.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.29.2026 - EX-99.1 EX-99.1
• 04.29.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.29.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.29.2026 - 8-K Current report
• 04.24.2026 - ARS Annual Report to Security Holders
• 04.24.2026 - DEF 14A Other definitive proxy statements
• 04.24.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.06.2026 - 4 Statement of changes in beneficial ownership of securities